Advertisement
Canada markets close in 6 hours 15 minutes
  • S&P/TSX

    22,272.14
    +28.12 (+0.13%)
     
  • S&P 500

    5,540.59
    +3.57 (+0.06%)
     
  • DOW

    39,325.03
    +17.03 (+0.04%)
     
  • CAD/USD

    0.7336
    -0.0011 (-0.15%)
     
  • CRUDE OIL

    83.84
    -0.04 (-0.05%)
     
  • Bitcoin CAD

    75,987.12
    -1,509.77 (-1.95%)
     
  • CMC Crypto 200

    1,155.51
    -53.18 (-4.40%)
     
  • GOLD FUTURES

    2,388.20
    +18.80 (+0.79%)
     
  • RUSSELL 2000

    2,030.49
    -6.14 (-0.30%)
     
  • 10-Yr Bond

    4.3020
    -0.0530 (-1.22%)
     
  • NASDAQ

    18,232.75
    +44.45 (+0.24%)
     
  • VOLATILITY

    12.32
    +0.06 (+0.49%)
     
  • FTSE

    8,237.34
    -3.92 (-0.05%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     
  • CAD/EUR

    0.6772
    -0.0020 (-0.29%)
     

Genetic Signatures Limited (ASX:GSS) is definitely on the radar of institutional investors who own 44% of the company

Key Insights

  • Given the large stake in the stock by institutions, Genetic Signatures' stock price might be vulnerable to their trading decisions

  • A total of 6 investors have a majority stake in the company with 51% ownership

  • Past performance of a company along with ownership data serve to give a strong idea about prospects for a business

Every investor in Genetic Signatures Limited (ASX:GSS) should be aware of the most powerful shareholder groups. With 44% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.

ADVERTISEMENT

Let's delve deeper into each type of owner of Genetic Signatures, beginning with the chart below.

View our latest analysis for Genetic Signatures

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Genetic Signatures?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Genetic Signatures already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Genetic Signatures, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Genetic Signatures. Asia Union Investments Pty Limited is currently the largest shareholder, with 20% of shares outstanding. With 12% and 8.8% of the shares outstanding respectively, Perennial Value Management Limited and Fidelity International Ltd are the second and third largest shareholders.

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of Genetic Signatures

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Shareholders would probably be interested to learn that insiders own shares in Genetic Signatures Limited. As individuals, the insiders collectively own AU$4.0m worth of the AU$151m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

The general public, who are usually individual investors, hold a 36% stake in Genetic Signatures. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Company Ownership

It seems that Private Companies own 3.9%, of the Genetic Signatures stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 2 warning signs we've spotted with Genetic Signatures (including 1 which can't be ignored) .

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.